Giancarlo Grossi
University of Genoa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Giancarlo Grossi.
European Journal of Medicinal Chemistry | 2000
Giorgio Roma; Mario Di Braccio; Giancarlo Grossi; Francesca Mattioli; Marco Ghia
The title compounds (8) were synthesized through the cyclocondensation of the corresponding N-substituted 4-amino-2-chloro-1,8-naphthyridine-3-carboxamides (4) with the proper hydrazides, in order to evaluate their anti-inflammatory and anti-aggressive properties. Several compounds 8 exhibited high anti-inflammatory activity (carrageenin-induced paw edema assay in the rat) along with appreciable anti-aggressive properties (isolation-induced aggressiveness test in mice). With respect to anti-inflammatory activity, the most active compounds (8n and 8c) produced a 61% edema inhibition at the 25 mg/kg dose, and 50 or 35% inhibition, respectively, at the 12.5 mg/kg dose. The structure-activity relationships are discussed.
European Journal of Medicinal Chemistry | 2001
Mario Di Braccio; Giancarlo Grossi; Giorgio Roma; Laura Vargiu; Massimo Mura; Maria Elena Marongiu
A number of properly substituted 5H-pyrimido[4,5-b][1,5]benzodiazepines (2) and pyrazolo[3,4-b][1,5]benzodiazepines (3 and 4), as well as compounds 5-7, which are derivatives of new tetracyclic systems, were prepared as nevirapine analogues through multistep synthetic routes. The cytotoxic and anti-HIV-1 properties of compounds 2-7 were evaluated in cell-based assays, together with their inhibitory activity against the HIV-1 recombinant reverse transcriptase (rRT) in enzyme assays. The modifications introduced into nevirapine heterocyclic skeleton proved to have a negative effect for the anti-HIV-1 activity. It is worth noting that some of the new derivatives proved to be cytotoxic in the low micromolar range.
Bioorganic & Medicinal Chemistry | 2003
Giorgio Roma; Mario Di Braccio; Antonio Carrieri; Giancarlo Grossi; Giuliana Leoncini; Maria Grazia Signorello; Angelo Carotti
As a further part of our chemical and biological studies in this field, we describe the multistep preparations of the properly substituted 2-(1-piperazinyl)chromone 1b, 4-(1-piperazinyl)coumarins 5c-h, their linear benzo-fused analogues 4a,b and 8a,b, bicyclic (15e-g) and tricyclic (15h,i) fused derivatives of 6-(1-piperazinyl)pyrimidin-4(3H)-one, and of the 4H-pyrido[1,2-a]pyrimidine derivatives 9b,c. The in vitro evaluation of their inhibitory properties towards human platelet aggregation induced in platelet-rich plasma by ADP, collagen, or the Ca (2+)ionophore A23187 showed the high activity of compounds 5d-g and 15f,g,i, among which the coumarins 5g and 5d proved to be, in that order, the most effective in vitro antiplatelet agents until now synthesized by us. Thus, in order to consider also the 4-aminocoumarin structural class, we developed a new statistically significant 3-D QSAR model, more general than the one previously obtained, through a further CoMFA study based on the antiplatelet activity data and molecular steric and electrostatic potentials of both the previously studied and herein described compounds.
European Journal of Medicinal Chemistry | 2002
Giancarlo Grossi; Mario Di Braccio; Giorgio Roma; Vigilio Ballabeni; Massimiliano Tognolini; Francesco Calcina; Elisabetta Barocelli
The reaction of proper N,N-dialkyl-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines (1) with N-chlorosuccinimide afforded their 4-chloroderivatives 3 which in turn were treated with cyclic amines to give the corresponding 4,5-diaminoderivatives 4. The N,N-dialkyl-4H-imidazo[1,2-a][1,5]benzodiazepin-5-amines (5) were prepared starting from suitable 4-(dialkylamino)-1,3-dihydro-2H-1,5-benzodiazepin-2-ones (8), through multistep synthetic routes. At the 200 mg kg(-1) os dose, some compounds 3 and 4 showed notable analgesic or anti-inflammatory activity but no antipyretic properties, whereas the 5-(dibutylamino) derivatives 5b and 5f proved to be significantly endowed with all these activities. Almost all the compounds 3, 4 and 5 did not show acute toxicity in mice up to 800 mg kg(-1) os dose.
Bioorganic & Medicinal Chemistry | 2000
Giorgio Roma; Nunzia Cinone; Mario Di Braccio; Giancarlo Grossi; Giuliana Leoncini; Maria Grazia Signorello; Angelo Carotti
2-(1-Piperazinyl)-4H-pyrido[1,2-a]pyrimidin-4-one (5a) is a recently described in vitro inhibitor of human platelet aggregation which specifically inhibits the activity of high affinity cAMP phosphodiesterase. A number of substitution derivatives, isosteres, and analogues of 5a were now synthesized and tested in vitro for their inhibitory activity on human platelet aggregation induced in platelet-rich plasma by ADP, collagen, or the Ca2+ ionophore A23187. Among the most effective compounds, the 6-methyl, 8-methyl and 6,8-dimethyl derivatives of 5a resulted nearly as active as the lead when platelet aggregation was induced by ADP or A23187, but less active when collagen was the inducer. On the basis of present results and those previously obtained by us in this and 2-aminochromone structural fields, we have developed a statistically significant 3-D QSAR model, using comparative molecular field analysis (CoMFA), describing the variation of the antiplatelet activity in terms of molecular steric and electrostatic potential changes.
European Journal of Medicinal Chemistry | 1991
Giorgio Roma; Giancarlo Grossi; M Di Braccio; Marco Ghia; Francesca Mattioli
Abstract A new two-step synthetic pathway to substituted 4 H -[1,2,4]triazolo[4,3- a ][1,5]benzodiazepin-5-amines 2a–p is described. The cyclocondensation of (dimethylamino)benzodiazepinone 1a with hydrazides afforded triazolobenzodiazepinones 5 which in turn reacted with suitable primary or secondary amines, in the presence of titanium tetrachloride, to give the desired 5-amino-derivatives 2a–p . When compounds 5 were treated with the Lawessons reagent thiolactams 6 were obtained, which then reacted with sodium hydride and proper alkyl halides to yield 5-(alkylthio)derivatives 7a–d . Compounds 2a–h, j–p , and 7a–d were tested for their analgesic and anti-inflammatory activities, as well as for their acute toxicity and gross behavioral effects. The analgesic activity appeared noteworthy in the writhing test, where fifteen compounds were more effective than both the reference drugs acetylsalicyclic acid and dipyrone, but was less evident in the hot plate test. An anti-inflammatory activity, lower than that of indomethacin but reaching the level of statistical significance, was displayed in the carrageenin-induced edema assay by five of the nineteen test compounds.
Farmaco | 2003
Mario Di Braccio; Giancarlo Grossi; Giorgio Roma; Cristina Marzano; Franca Baccichetti; Morena Simonato; Franco Bordin
The N-substituted tricyclic 2-aminochromone derivatives 1a, 2a, and 2b were obtained by treating the corresponding (methylthio) or (methylsulfinyl) derivatives 10, 11, or 12, respectively, with an excess of the proper amines. Compound 2c was synthesized through the reaction of 2-naphthol with the ethyl N,N-diphenylmalonamate/POCl(3) reagent 14. The N-substituted 4-aminocoumarin bicyclic and tricyclic derivatives 5-8 were prepared by treating the corresponding chloro derivatives with the excess suitable amines. Compounds 1, 2, 5-8 were tested in vitro for their antiproliferative activity (DNA synthesis inhibition in Ehrlich cells) and cytotoxicity (MTT test in HeLa cells). The inhibitory properties of three selected compounds (5c, 5e, 7c) on protein and RNA syntheses in Ehrlich cells were also evaluated. Among the 27 compounds tested, 10 4-aminocoumarin derivatives (5-8) and two 2-aminochromone derivatives (1a and 2a) showed an appreciable antiproliferative activity (IC(50) range: 1.74-13.8 microM), whereas only four compounds 5-8 exhibited a comparable cytotoxic activity (IC(50) range: 4.95-12.9 microM).
European Journal of Medicinal Chemistry | 2010
Giorgio Roma; Mario Di Braccio; Giancarlo Grossi; Daniela Piras; Vigilio Ballabeni; Massimiliano Tognolini; Simona Bertoni; Elisabetta Barocelli
On the basis of the very interesting pharmacological properties shown by the 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamide derivatives 1, previously described by us, we have now prepared the 5-aminoimidazo[1,2-a][1,8]naphthyridine-6-carboxamide derivatives 2a-o (a new structural class) whose tricyclic system is isosteric to that of compounds 1. Both compounds 2 and some new properly substituted compounds 1 (1f-k) now synthesized were tested in vivo for their analgesic and anti-inflammatory activities: on the whole, compounds 2 showed notable analgesic properties, whereas many compounds 1 exhibited a very potent anti-inflammatory activity, coupled to scarce analgesic activity. All the effective compounds proved to be completely devoid of acute gastrolesivity (gastric damage) in rats (at the 200 mg kg(-1) oral dose).
European Journal of Medicinal Chemistry | 1990
M Di Braccio; Giorgio Roma; Giancarlo Grossi; Marco Ghia; E Mereto
The reaction of N,N-disubstituted 4-(methylthio)-3H-1,5-benzodiazepin-2-amines 8 with formylhydrazine, acetylhydrazine or benzoylhydrazine afforded the expected N,N-disubstituted 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines 9, along with lower yields of tetracyclic compounds 10. A number of compounds 9 and 10 were tested for their analgesic, anti-inflammatory and anticonvulsant activities, as well as for their acute toxicity and gross behavioral effects. Dipyrone, indomethacin and phenobarbital were used as reference drugs. Some compounds 9 showed statistically significant analgesic or anti-inflammatory properties, depending on the structure.
European Journal of Medicinal Chemistry | 2013
Leonardo Pisani; Marco Catto; Orazio Nicolotti; Giancarlo Grossi; Mario Di Braccio; Ramón Soto-Otero; Estefanía Méndez-Álvarez; Angela Stefanachi; Domenico Gadaleta; Angelo Carotti
The effects on the inhibition potencies of monoamine oxidase isoforms A (MAO-A) and B (MAO-B) depending upon changes in the physicochemical properties (size, shape, H-bonding, lipophilicity, etc.) of substituents at the C4 position of 2H-chromen-2-one derivatives were extensively investigated, and the results significantly added to our knowledge on this class of MAO inhibitors. All the 67 examined compounds showed high MAO-B selectivity, some of them achieving potency in the low nanomolar range. In particular, the 7-metachlorobenzyloxy-4-oxyacetamido-2H-chromen-2-one (entry 62) showed single digit nanomolar MAO-B potency (IC₅₀ = 3.1 nM) and high selectivity over the MAO-A isoform (selectivity ratio = 7244). The great variety of the investigated substituents at C4 of the 2H-chromen-2-one nucleus, combined with binding models generated from docking studies carried out on selected compounds, allowed us to shed light on the main molecular requirements for potent and selective MAO-B inhibition, highlighting the dominant role of the steric effects. Interestingly, many of the designed substituents could be metabolically related to each other (e.g., CH₃/CH₂OH/CHO/COOH; NH₂/NHCH₃, NHAc), and therefore the results obtained may help in predicting the in vivo activity of some putative metabolites of lead MAO-B inhibitors.